Volume 21, Issue 7 e13035
ORIGINAL ARTICLE

Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients

Andrew M. South

Corresponding Author

Andrew M. South

Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA

Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston Salem, NC, USA

Correspondence

Andrew M. South, Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA.

Email: [email protected]

Search for more papers by this author
Lynn Maestretti

Lynn Maestretti

Pediatric Renal Transplant Program, Lucile Packard Children's Hospital at Stanford, Stanford, CA, USA

Search for more papers by this author
Neeraja Kambham

Neeraja Kambham

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

Search for more papers by this author
Paul C. Grimm

Paul C. Grimm

Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Search for more papers by this author
Abanti Chaudhuri

Abanti Chaudhuri

Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Search for more papers by this author
First published: 22 August 2017
Citations: 1

Abstract

Pediatric renal transplant recipient survival continues to improve, but ABMR remains a significant contributor to graft loss. ABMR prognostic factors to guide treatment are lacking. C4d staining on biopsies, diagnostic of ABMR, is associated with graft failure. Persistent C4d+ on follow-up biopsies has unknown significance, but could be associated with worse outcomes. We evaluated a retrospective cohort of 17 pediatric renal transplant patients diagnosed with ABMR. Primary outcome at 12 months was a composite of ≥50% reduction in eGFR, transplant glomerulopathy, or graft failure. Secondary outcome was the UPCR at 12 months. We used logistic and linear regression modeling to determine whether persistent C4d+ on follow-up biopsy was associated with the outcomes. Forty-one percent reached the primary outcome at 12 months. Persistent C4d+ on follow-up biopsy occurred in 41% and was not significantly associated with the primary outcome, but was significantly associated with the secondary outcome (estimate 0.22, 95% CI 0.19-0.25, < .001), after controlling for confounding factors. Persistent C4d+ on follow-up biopsies was associated with a higher UPCR at 12 months. Patients who remain C4d+ on follow-up biopsy may benefit from more aggressive or prolonged ABMR treatment.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.